Feedback PLC Collaboration with the Oxford Stone Group (9214J)
13 April 2015 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 9214J
Feedback PLC
13 April 2015
13 April 2015
Feedback plc
("Feedback", the "Company" or the "Group")
Collaboration with the Oxford Stone Group, University of Oxford
& Oxford University Hospital NHS Trust, Oxford, UK
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce that it has signed a research agreement with
the Oxford Stone Group at the University of Oxford & Oxford
University Hospital NHS Trust ("Oxford") in Oxford, UK to
investigate the potential clinical application of Feedback's TexRAD
texture analysis software on CT image data of patients with kidney
stones.
The research collaboration will be led by Mr Ben Turney (Bernard
Senior Clinical Researcher in Urology at the University of Oxford
and Honorary Consultant Urological Surgeon) and Mr Daniel Stevens
(Academic Clinical Fellow in Urology at the University of Oxford).
As part of the Oxford Stone Group, Mr Turney is developing an
international reputation for innovative and original research into
the causes and treatment of urological stone disease.
The field of kidney stone management includes all forms of
detection diagnosis and treatment of stones. In the UK, an
estimated 85,000 patients attend hospital with kidney stones each
year. Treatment options include Shock Wave Lithotripsy (an
ultrasound based shock wave technique to break up the stones after
which the tiny pieces of stone pass out of the body in the urine)
or endoscopic surgery to fragment the stones using lasers. Around
40,000 treatments for kidney stones are performed in the UK each
year. Stones commonly affect people between the ages of 20 and 60
and consequently the combined direct costs of treatment and
indirect costs in terms of days off work are very considerable.
The majority of stone patients undergo CT scans as part of their
diagnostic evaluation. TexRad based CT texture analysis of the
stones in these scans might improve several aspects of stone
management:
1) Diagnostic accuracy
Often there are other features on scans that can be confused
with kidney stones (mimics such as phleboliths, calcification in
arteries and calcified nodes). Image analysis might increase the
diagnostic confidence and prevent unnecessary costly investigation
and treatments.
2) Prediction of response to different treatments
Some stones respond well to shock wave lithotripsy while others
are resistant. Image analysis might allow accurate triaging of
patients to the correct treatment first time. This would have clear
cost benefits to clinical services.
3) Determination of stone composition
Image analysis might allow correlation with stone composition.
This would be important in advising the patient about prevention
strategies
Potentially, these benefits could be extracted from images that
are routinely acquired for patients with kidney stones.
Identifying which patients will benefit from lithotripsy would
help to streamline treatment pathways and better allow clinicians
to advise patients in choosing the right option for them.
Similarly, using a non-invasive tool to better evaluate the
composition of the stone facilitates personalised advice.
Initially Mr Turney and his team will be undertaking a pilot
study of 100 patients with kidney stones on KUB CT, with four key
objectives:
-- TexRAD analysis of the stone on CT to look for any variation
in stone characteristics. What is the heterogeneity between
different stones and within individual stones?
-- Evaluate the relationship between the TexRad score and
clinical outcome from shock wave lithotripsy in an independent
cohort of patients.
-- Correlate TexRad parameters and stone composition determined
by the gold standard FTIR analysis.
-- Characterise the TexRad differences between stones and other mimics.
Feedback plc is focused on establishing the use of TexRAD in
clinical practice. To achieve this, Feedback plc has established a
strong customer base and research collaborations with key opinion
leaders at world class imaging research centres and hospitals
around the world. The research collaboration with the University of
Oxford & Oxford University Hospital NHS Trust is another such
example.
Mr Ben Turney, a leading authority on stone disease in the UK,
commented:
"The prevalence of kidney stone disease is increasing globally.
There is an important need to continue to develop and improve
technology that will support personalised care in the management of
patients with kidney stones. Feedback's TexRAD software offers the
potential for important advances in this field. TexRAD captures key
heterogeneity information, which will be crucial in understanding
stone characteristics in a non-invasive and cost-effective manner
from routinely acquired diagnostic CT images. This will potentially
assist in more accurate patient risk-stratification and treatment
decision choices."
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer,
TexRAD Ltd & CCI (both part of Feedback plc) commented:
"Mr Turney is a leading stone expert in the UK and we are
delighted that he will be leading the research team working with
our TexRAD software. The Oxford Stone Group as part of the
University of Oxford and Oxford University Hospital NHS Trust is a
leading research centre in the United Kingdom and we are delighted
to be working with them and enhancing our TexRAD research
collaborator base with the addition of another key site and opinion
leader in the region."
For further information contact:
Feedback plc Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom Charlton
Sanlam Securities UK (Nominated Adviser and Joint Broker)
Simon Clements / Virginia Bull Tel: 020 7628
2200
Peterhouse Corporate Finance Ltd (Joint Tel: 020 7469
Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging-Biomarker') in confident decision-making: assessing
the prognosis, disease-severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'.TexRAD is manufactured
under licence by the ISO 13485 certified company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRSFAFISFISESL
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024